1-(4-甲基苄基)高哌嗪 | 110766-00-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-甲基苄基)高哌嗪
• 英文名称: 1-[(4-Methylphenyl)methyl]-1,4-diazepane
• CAS: 110766-00-2
• 化学式: C₁₃H₂₀N₂
• mdl: MFCD07383227
• 分子量: 204.315
• InChiKey: IXRSALZMDNNZTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-甲基苄基)高哌嗪 、 2-chloro-N-(1-oxo-1,2,4,5-tetrahydro-[1,2,4]triazolo[4,3-a]quinolin-7-yl)acetamide 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 10.0h， 生成 2-[4-[(4-methylphenyl)methyl]-1,4-diazepan-1-yl]-N-(1-oxo-4,5-dihydro-2H-[1,2,4]triazolo[4,3-a]quinolin-7-yl)acetamide
  参考文献：
  名称：

  Synthesis and positive inotropic evaluation of N-(1-oxo-1,2,4,5-tetrahydro-[1,2,4]triazolo[4,3-a]quinolin-7-yl)acetamides bearing piperazine and 1,4-diazepane moieties

  摘要：

  Two series of N-(1-oxo-1,2,4,5-tetrahydro-[1,2,4]triazolo[4,3-a]quinolin-7-yl)acetamides bearing piperazine and 1,4-diazepane moieties were synthesized and screened for their positive inotropic activity by measuring left atrium stroke volume on isolated rabbit heart preparations. Most of the derivatives exhibited better in vitro positive inotropic activity than the existing drug, milrinone, among which 2-(4-(4-chlorobenzyl)-1,4-diazepan-1-yl)-N-(1-oxo-1,2,4,5-tetrahydro-[1,2,4] triazolo[4,3-a]quinolin-7-yl) acetamide 6c proved to be the most potent with 15.48 +/- 0.27% increased stroke volume (milrinone: 2.46 +/- 0.07%) at a concentration of 3 x 10 (5) M. The chronotropic effects of the compounds that exhibited inotropic effects were also evaluated. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.049

文献信息

• 1-Substituted Alkyl-1, 2-Dihydro-2-Pyrazinone derivatives
  申请人：TOYO JOZO KABUSHIKI KAISHA

  公开号：EP0242957A1

  公开（公告）日：1987-10-28

  Compounds of formula (I) wherein R is hydroxyl, halogen, lower alkanoyloxy, R4-carbamoyloxy, arylthio, 1-methyltetrazole-5-yl-thio, 1-imidazolyl, morpholino, or in which R4 is lower alkyl or aryl, Rs is hydrogen, lower alkyl or aryl, R6 is hydrogen, lower alkyl, hydroxy-lower alkyl, aryl, aryl-lower alkanoyl, arylcarbonyl, arylsulfonyl or thienyl-lower alkanoyl, A and A, are lower alkylene, m is an integer of from 4 to 6, n is the integer 2 or 3; R, is alkyl aryl-lower alkyl or aryl; and R2 and R3 are each lower alkyl or together constitute tetramethylene; and pharmacologically acceptable non-toxic salts thereof; wherein aryl means phenyl unsubstututed or substituted by C1-3 alkyl, halogen, nitro or lower alkoxyl; have an inhibitory action on platelet aggregation, vasodilating activity and/or inhibitory action on lipoperoxide generation.

  式(I)化合物 其中 R 是羟基、卤素、低级烷酰氧基、R4-氨基甲酰氧基、芳硫基、1-甲基四唑-5-硫基、1-咪唑基、吗啉基、 或 其中 R4 是低级烷基或芳基，Rs 是氢、低级烷基或芳基，R6 是氢、低级烷基、羟基-低级烷基、芳基、芳基-低级烷酰基、芳基羰基、芳基磺酰基或噻吩基-低级烷酰基，A 和 A，是低级亚烷基，m 是 4 到 6 的整数，n 是 2 或 3 的整数；R，是烷基芳基-低级烷基或芳基；以及 R2 和 R3 分别为低级烷基或共同构成四亚甲基；及其药理上可接受的无毒盐；其中芳基指未被 C1-3 烷基、卤素、硝基或低级烷氧基取代或取代的苯基；具有抑制血小板聚集的作用、血管扩张活性和/或抑制脂过氧化物生成的作用。
• 2-Substituted alkoxy-3-substituted-pyrazines
  申请人：TOYO JOZO KABUSHIKI KAISHA

  公开号：EP0252670A2

  公开（公告）日：1988-01-13

  A compound which is a pyrazine derivative of formula wherein: Q is -CO-or -CH2-, R is hydroxyl, C1-C4 alkoxy, a halogen, -NH-C1-C4 alkylene-OH, -NH-C1-C4 alkylene-arylthio,-NH-C1-C4 alkylene-halogen, in which is di-Ci-C4-alkylamino, cycloalkylamino, morpholino, alkylene-aryl or in which R9 is hydrogen, C1-C4 alkyl or aryl, R10 is hydrogen, C1-C4 alkyl, hydroxy-C1-C4 alkyl, hydroxy-C1-C4 alkoxy-C1-C4 alkyl or di(aryl)-C1-C4 alkyl, m is an integer of 4 to 6, n is 2 or 3, R1 is alkyl or aryl-C1-C4 alkyl, R2 and R3 are independently each C1-C4 alkyl, or together form a tetramethylene bridge, and R4 is hydrogen, C1-C4 alkyl or phenyl, which phenyl is optionally substituted by 1 to 3 halogens, a nitro, a C1-C4 alkyl or a C1-C4 alkoxy group, or a pharmaceutically acceptable salt thereof, is useful in the treatment of circulatory or metabolic disorders.

  一种化合物，它是式中的吡嗪衍生物 其中 Q为-CO-或-CH2-、 R是羟基、C1-C4烷氧基、卤素、-NH-C1-C4亚烷基-OH、-NH-C1-C4亚烷基芳硫基、-NH-C1-C4亚烷基卤素、 其中 是二-Ci-C4-烷基氨基、环烷基氨基、吗啉基、 烯芳基或 其中 R9 为氢、C1-C4 烷基或芳基，R10 为氢、C1-C4 烷基、羟基-C1-C4 烷基、羟基-C1-C4 烷氧基-C1-C4 烷基或二(芳基)-C1-C4 烷基，m 为 4-6 的整数，n 为 2 或 3、 R1 是烷基或芳基-C1-C4 烷基、 R2 和 R3 各自独立地为 C1-C4 烷基，或共同形成四亚甲基桥，以及 R4 是氢、C1-C4 烷基或苯基，其中苯基可任选被 1 至 3 个卤素、硝基、C1-C4 烷基或 C1-C4 烷氧基取代、 或其药学上可接受的盐，可用于治疗循环或代谢紊乱。
• Synthesis of 2-(4-substituted benzyl-1,4-diazepan-1-yl)-N-(3,4-dihydro-3-oxo-2H-benzo[b][1,4]oxazin-7-yl)acetamides and their positive inotropic evaluation
  作者：Kun Yang、Liang-Peng Sun、Ji-Yong Liu、Xun Cui、Hu-Ri Piao

  DOI：10.1016/j.bmcl.2010.06.046

  日期：2010.8

  Herein we describe the discovery of compound 3g, a potent positive inotropic agent compared with the standard drug, milrinone. Compound 3g was developed from a series of 2-(4-substitutedbenzyl-1,4-diazepan- 1-yl)-N-(3,4-dihydro-3-oxo-2H-benzo[b][1,4] oxazin-7-yl) acetamides found in an evaluation of inotropic activity by measuring left atrium stroke volume on isolated rabbit heart preparations. Several compounds showed favorable activities, but 3g was the most potent, with 7.68 +/- 0.14% increased stroke volume (milrinone 2.38 +/- 0.05%) at 1 x 10 (5) M in our in vitro study. The chronotropic effects of compounds having significant inotropic effects were also evaluated. (C) 2010 Elsevier Ltd. All rights reserved.
• US4769366A
  申请人：——

  公开号：US4769366A

  公开（公告）日：1988-09-06
• US4826974A
  申请人：——

  公开号：US4826974A

  公开（公告）日：1989-05-02